#### GLYCOPYRROLATE- glycopyrrolate tablet Endo USA, Inc.


-----

# GLYCOPYRROLATE TABLETS, USP Rx only

#### DESCRIPTION

Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name:

3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. Its empirical formula is  $C_{19}H_{28}BrNO_3$ , its molecular weight is 398.33, and its structural formula is:



Each 1 mg tablet contains: Glycopyrrolate, USP 1mg

Each 2 mg tablet contains: Glycopyrrolate, USP 2mg

Inactive Ingredients: Dibasic Calcium Phosphate, Lactose, Magnesium Stearate, Povidone, Sodium Starch Glycolate.

## ACTIONS

Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.

The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

## INDICATIONS

For use as adjunctive therapy in the treatment of peptic ulcer.

## CONTRAINDICATIONS

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

#### WARNINGS

In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of glycopyrrolate.

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomyor colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

Glycopyrrolate may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.

Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

## Pregnancy

The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.

## **Nursing Mothers**

It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

## **Pediatric Use**

Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

## PRECAUTIONS

Use glycopyrrolate with caution in the elderly and in all patients with:

- Autonomic neuropathy.
- Hepatic or renal disease.
- Ulcerative colitis-large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate "toxic megacolon," a serious complication of the disease.
- Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.
- Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.

# ADVERSE REACTIONS

Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

Glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.

# OVERDOSAGE

The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

- 1. To guard against further absorption of the drug-use gastric lavage, cathartics and/or enemas.
- 2. To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.)utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
- 3. To combat hypotension-use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
- 4. To combat respiratory depression-administer oxygen; utilize a respiratory stimulant such as Dopram<sup>®</sup> i.v.; artificial respiration.

# DOSAGE AND ADMINISTRATION

The dosage of glycopyrrolate should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

**Glycopyrrolate Tablets 1 mg.** The recommended initial dosage of glycopyrrolate for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms. For maintenance, a dosage of one tablet twice a day is frequently adequate.

**Glycopyrrolate Tablets 2 mg.** The recommended dosage of glycopyrrolate for adults is one tablet two or three times daily at equally spaced intervals.

Glycopyrrolate tablets are not recommended for use in pediatric patients under the age of 12 years.

## DRUG INTERACTIONS

There are no known drug interactions.

## HOW SUPPLIED

Glycopyrrolate tablets 1 mg are bisected, compressed white, round tablets debossed "K" above the bisect and "400" below the bisect on one side of the tablet, and plain on the other side.

Available in bottles of 100 (NDC 49884-065-01).

Glycopyrrolate tablets 2 mg are bisected, compressed white, round tablets debossed "K" above the bisect and "401" below the bisect on one side of the tablet, and plain on the other side.

Available in bottles of 100 (NDC 49884-066-01).

# Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59 to 86°F) [See USP Controlled Room Temperature].

## Keep out of reach of children.

## Dispense in a tight container.

Manufactured for: Endo USA Malvern, PA 19355 U.S.A Product of Finland Made in India

Neutral Code: TN/DRUGS/ TN00002121 © 2024 Endo, Inc. or one of its affiliates.

from Active Pharmaceutical Ingredient made in Finland

OS065-01-74-04 Revised: 08/2024

## PRINCIPAL DISPLAY PANEL - 1MG/100'S LABEL



#### PRINCIPAL DISPLAY PANEL - 2MG/100'S LABEL

NDC 49884- <b>066</b> -01	Each tablet contains: Glycopyrrolate, USP	LA066-01-74-04 R08/24	
Glycopyrrolate Tablets, USP	<b>USUAL DOSAGE:</b> One tablet two or three times a day. See accompanying information.	01121	N)
2 mg	KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.	U.S.A initand Soluces/TN00	
Rx only	Pharmacist: Dispense in a tight container.		
100 Tablets	Store at 20° to 25°C (68° to 77°F);	Ctured for SA A 1935 t of Finlan ent made i Code: TN Code: TV	
🥏 endo	excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].	Manufa Endo Ufa Malveru Product Ingredic S	

GLYCOPYRROLATE glycopyrrolate tablet					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:49884-065		
Route of Administration	ORAL				
Active Ingredient/Active Moiety					
Ingredient Name		Basis of Stre	ength Strength		

Strength

	tive Ingree	dients				
Ingredient Name					Strength	
CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: O7TSZ97GEP)						
LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G)						
MAGN	ESIUM STEAR	RATE (UNII:	70097M6I30)			
	ONE (UNII: FZ					
SODIU	JM STARCH G	LYCOLATE	ΤΥΡΕ Α ΡΟΤΑ	<b>TO</b> (UNII: 5856J3G2A2	2)	
Prod	luct Chara	cteristic	S			
Color	•	N	/hite	Score		2 pieces
Shape	е	R	OUND	Size		
Flavo	r			Imprint Code	Imprint Code	
Conta	ains					
Pack	caging					
# Ite	em Code	Р	ackage De	scription	Marketing Start Date	Marketing End Date
1 NDC		100 in 1 BO Product	TTLE; Type 0:	Not a Combination	09/26/2006	
		-	tion			
Mar	'keting l	nforma	ition			
м	<b>keting  </b> larketing Category			er or Monograph tion	Marketing Start Date	Marketing End Date
M C	-		cation Numb Cita		-	•
М	larketing	Applic	cation Numb Cita		Date	Marketing End Date
M C	larketing	Applic	cation Numb Cita		Date	-
M C ANDA	larketing Category	Applic	cation Numb Cita		Date	•
M C ANDA	larketing Category	Applic ANDA040 OLATE	cation Numb Cita		Date	-
M C ANDA	larketing Category	Applic ANDA040 OLATE	cation Numb Cita		Date	•
M C ANDA GLY( glycop	larketing Category	Applic ANDA0400 OLATE let	cation Numb Cita		Date	•

Product Type
HUMAN PRESCRIPTION DRUG
Item Code (Source)
NDC:49884-066

Route of Administration
ORAL

<td

Active Ingredient/Active Moiety					
Ingredient Name	<b>Basis of Strength</b>	Strength			
GLYCOPYRROLATE (UNII: V92SO9WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D)	GLYCOPYRROLATE	2 mg			
Inactive Ingredients					

**Ingredient Name** 

•							
		ATE, DIBASIC, DIHYDRATE					
	LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G)						
	MAGNESIUM STEARATE (UNII: 70097M6I30)						
	POVIDONE (UNII: FZ 989GH94E)						
SO	SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)						
Product Characteristics							
Co					2 pieces		
Sh	ape	ROUND	Size				
Fla	vor Imprint Code		K;401				
Co	ontains						
Pa	ackaging						
#	ltem Code	Package Des	cription	Marketing Start Date	Marketing End Date		
1	NDC:49884-066- 01	100 in 1 BOTTLE; Type 0: N Product	1 BOTTLE; Type 0: Not a Combination t				
Μ	Marketing Information						
	Marketing Category	Application Numbe Citat		Marketing Start Date	Marketing End Date		
AN	DA	ANDA040653		09/26/2006			

Labeler - Endo USA, Inc. (119185057)

Revised: 8/2024

Endo USA, Inc.